Pharmacy Prior Authorization Criteria

Leqselvi (deuruxolitinib)

Indications for Prior Authorization

Leqselvi (deuruxolitinib)

• For diagnosis of Alopecia Areata
  Indicated for the treatment of adult patients with severe alopecia areata.

  Limitations of use: Leqselvi is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants.

Criteria

Leqselvi

Prior Authorization (Initial Authorization)

Length of Approval: 12 Month(s)
For diagnosis of Alopecia Areata

• Diagnosis of alopecia areata
AND
• Patient has at least 50% scalp hair loss [1, 2]
AND
• Other causes of hair loss have been ruled out (e.g., other types of alopecia, scalp disease, active systemic disease) [2]
AND
• Prescribed by or in consultation with a dermatologist
AND
• Not used in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants*

Leqselvi

Prior Authorization (Reauthorization)

Length of Approval: 12 Month(s)
For diagnosis of Alopecia Areata

• Patient demonstrates positive clinical response to therapy
AND
• Not used in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants*

P & T Revisions

2026-06-14, 2026-02-04, 2025-12-17, 2025-11-07, 2025-10-02, 2025-07-08

References

1. Leqselvi Prescribing Information. Sun Pharmaceutical Industries, Inc. Whippany, NJ. July 2024.
2. King B, Senna MM, Mesinkovska NA, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. 2024; 91(5):880-888.

---

Revision History

• 2026-06-14: Annual review - Updated examples of other causes of hair loss to better align with clinical trials; no change to clinical intent; reference updates
• 2026-02-04: Removed drug-specific NF criteria
• 2025-12-17: no criteria changes, added IL statute operational note
• 2025-11-07: Added a 3-month trial duration to the steps through preferred alternatives in the NF criteria
• 2025-10-02: Removed step requirement through Litfulo or Olumiant for PA criteria; added NF criteria that includes the step requirement
• 2025-07-08: New program

---